An antibody-based conditioning agent may open the way to wider application of gene therapy with hematopoietic stem cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bacigalupo, A. et al. Biol. Blood Marrow Transplant. 15, 1628–1633 (2009).
Palchaudhuri, R. et al. Nat. Biotechnol. 34, 738–745 (2016).
Aiuti, A. et al. Science 296, 2410–2413 (2002).
Kohn, D.B. Hematology (Am. Soc. Hematol. Educ. Program) 2014, 475–480 (2014).
Cartier, N. et al. Science 326, 818–823 (2009).
Biffi, A. et al. Science 341, 1233158 (2013).
Czechowicz, A., Kraft, D., Weissman, I.L. & Bhattacharya, D. Science 318, 1296–1299 (2007).
Xue, X. et al. Blood 116, 5419–5422 (2010).
Liu, J. et al. PLoS One 10, e0137345 (2015).
Straathof, K.C. et al. Lancet 374, 912–920 (2009).
Notta, F. et al. Science 351, aab2116 (2016).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Aiuti, A., Naldini, L. Safer conditioning for blood stem cell transplants. Nat Biotechnol 34, 721–723 (2016). https://doi.org/10.1038/nbt.3629
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3629